10x Genomics, Inc. (NASDAQ: TXG) saw its stock surge 5.47% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results, the announcement of a strategic acquisition, and positive future guidance.

The biotechnology company significantly outperformed analyst expectations, reporting quarterly earnings of $0.28 per share, a dramatic turnaround from the $(0.32) per share loss reported in the same period last year. Revenue also exceeded expectations, coming in at $172.9 million, beating the analyst consensus estimate of $139.4 million by 24.02%. This strong performance marks a 12.93% increase in sales compared to the previous year. The company's gross margin improved to 72%, driven by higher license and royalty revenue.

Adding to the positive sentiment, 10x Genomics announced plans to acquire Scale Biosciences, a move expected to strengthen its single-cell analysis capabilities and potentially expand its market presence. Furthermore, the company provided an optimistic outlook for the third quarter of 2025, projecting revenue in the range of $140 million to $144 million. This combination of strong current performance, strategic expansion, and positive future guidance likely contributed to the stock's after-hours rally, despite ongoing challenges in the funding environment and market uncertainties.